Abstract: The present invention provides a polypeptide for preventing or treating idiopathic pulmonary fibrosis, which is synthesized by linking 9 to 10 amino acids together and comprises an amino acid sequence consisting of arginine (R, Arg)-glycine (G, Gly)-aspartic acid (D, Asp)-valine (V, Val)-phenylalanine (F, Phe)-proline (P, Pro)-serine (S, Ser)-tyrosine (Y, Tyr)-threonine (T, Thr). Accordingly, the polypeptide for preventing or treating idiopathic pulmonary fibrosis according to the present invention may restore lung function to normal by fundamentally treating lung tissue that has undergone fibrosis due to idiopathic pulmonary fibrosis, and furthermore, may delay or prevent the onset of idiopathic pulmonary fibrosis.

Abstract: A method for producing human pluripotent stem cell-derived cardiac organoids, includes: (A) preparing embryonic bodies having a diameter of 100 ?m to 130 ?m by culturing human pluripotent stem cells (hPSCs); (B) culturing the embryonic bodies, prepared in step (A), until the embryonic bodies have a diameter of 200 ?m to 250 ?m; (C) differentiating the human pluripotent stem cell-derived embryonic bodies having a diameter of 200 ?m to 250 ?m, obtained in step (B), into structures comprising mesoderm cells and endoderm cells; (D) differentiating the structures comprising mesoderm cells and endoderm cells, obtained in step (C), into cardiac organoids comprising self-organized cardiomyocytes, fibroblasts and vascular endothelial cells; and (E) culturing and maturing the cardiac organoids obtained by differentiation in step (D).

Abstract: A method of assessing drug cardiac safety using human stem cell-derived cardiomyocytes, includes: step (A) of preparing cardiomyocytes by culturing human stem cells to differentiate into cardiomyocytes; step (B) of diluting fibronectin in DPBS (Dulbecco's phosphate buffered saline) at a concentration of 50 ?g/ml; step (C) of adding the fibronectin solution, obtained by diluting to the concentration of 50 ?g/ml in step (B); step (D) of placing the MEA plate; step (E) of removing the fibronectin solution from specific wells of the MEA plate; step (F) of adding a predetermined medium to the specific wells of the MEA plate; and step (G) of measuring changes in information values about beat rate, spike amplitude and field potential duration depending on whether a drug to be assessed has been added to the wells of the MEA plate.

Abstract: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.

Abstract: The present invention relates to a recombinant protein for preventing or treating tissue fibrosis, which is based on milk fat globule-EGF factor 8 (MFG-E8) protein and comprises the amino acid sequence of SEQ ID NO: 1, and to a composition for preventing or treating tissue fibrosis, which comprises the recombinant protein. The level of the effect of preventing or treating tissue fibrosis by the recombinant protein of the present invention is significantly improved compared to that of conventional milk fat globule-EGF factor 8 (MFG-E8) protein, so that the level of tissue fibrosis can be restored to a level very close to that in normal tissue by the prevention and treatment of tissue fibrosis.